Clinical trials: Anakinra
Covid19
suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19
The SAVE-MORE is a pivotal, confirmatory, phase III randomized clinical trial (RCT) aiming to evaluate the efficacy and safety of early start of anakinra guided by suPAR in patients with LRTI by SARS-CoV-2 in improving the…
- Trial name
- SAVE-MORE (NCT04680949)
- Testing
- Anakinra
- Where
- 40 sites in Greece, Italy
- Volunteers
- 606 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Traumatic Brain INjury
IL-1ra Dose-range Study for Moderate-to-severe TBI Patients
Traumatic brain injury (TBI) is a common condition with high degree of morbidity and mortality (Hyder et al., 2007). Current treatment paradigms for TBI focus on mitigating secondary injury and maintaining cerebral physiology…
- Trial name
- IL1ra (NCT02997371)
- Testing
- Anakinra Prefilled Syringe, Isotonic saline
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Adel Helmy
Acute Alcoholic Hepatitis
Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
This study will compare two different treatments of acute alcoholic hepatitis. The current standard of care is treatment with corticosteroids (methylprednisolone).
- Trial name
- NCT01809132
- Testing
- Anakinra, Pentoxifylline, Zinc Sulfate
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Mack Mitchell
COVID-19, Virus Diseases
suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)
In the SAVE study patients with lower respiratory tract infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at high risk for progression to serious respiratory failure will be detected using the suPAR…
- Conditions
- COVID-19, Virus Diseases, Corona Virus Infection, Lower Respiratory Tract Infection Viral
- Trial name
- SAVE (NCT04357366)
- Testing
- Anakinra
- Where
- 28 sites in Greece
- Volunteers
- 1,000 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Diabetes Mellitus
Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus
The purpose of this study is to test whether anakinra is able to reduce insulin resistance. This will be tested in overweighted type I diabetes mellitus patients, which have no residual beta-cell function.
- Trial name
- NCT01285245
- Testing
- kineret
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Radboud University Medical Center
Giant Cell Arteritis
Giant Cell Arteritis and Anakinra Trial
SYNOPSIS The giant cell arteritis (GCA) is the most frequent vasculitis in people over 50 years. Despite recent progress and physiopathogenic, corticosteroids remains the standard treatment for decades with a very good initial…
- Trial name
- GiAnT (NCT02902731)
- Testing
- ANAKINRA
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Caen
B Cell ALL, B-Cell Lymphoma
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.
- Conditions
- B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
- Trial name
- NCT04148430
- Testing
- Anakinra
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kawasaki Disease
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery…
- Trial name
- NCT04747847
- Testing
- Atorvastatin and anakinra
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Diego
Chronic Kidney Disease, Cardiovascular Disease
Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
There has been an exponential growth in the number of people with Chronic Kidney Disease (CKD) needing dialysis or transplantation, increasing from 209,000 in 1991 to 472,000 in 2004.
- Trial name
- NCT00897715
- Testing
- Rilonacept
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
Metastatic Colorectal Cancer
Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer
The metastatic colon cancer is a major public health problem despite advances in chemotherapy; few new drugs are in development for the treatment of this pathology.
- Trial name
- IRAFU (NCT02090101)
- Testing
- ANAKINRA
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Centre Georges Francois Leclerc
Covid-19
A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
The study is designed as a randomized, controlled, multi-center open-label trial to compare standard-of-care (SOC) treatment with SOC + anakinra or SOC + tocilizumab treatment in hospitalized adult subjects who are diagnosed with…
- Trial name
- NCT04412291
- Testing
- Anakinra Prefilled Syringe, Tocilizumab Prefilled Syringe, Standard-of-care treatment
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska University Hospital
Covid19, Cytokine Storm
Anakinra, COVID-19, Cytokine Storm
The clinical syndrome associated with infection of the Coronavirus Disease 2019 (COVID-19) is notable for its variable clinical expression.
- Conditions
- Covid19, Cytokine Storm, Mechanical Ventilation Complication
- Trial name
- SOBI (NCT04603742)
- Testing
- Anakinra, 0.9% Saline
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Multiple Sclerosis
Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Background: Multiple sclerosis (MS) is a disease of the central nervous system (CNS). People who have MS may have lesions that form on parts of the CNS, such as the brain. Some of these lesions may be inflamed for a long time.
- Trial name
- NCT04025554
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Pancreas Cancer
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
The study's overall objectives are to evaluate the safety of anakinra in combination with standard chemotherapy regimens in patients with pancreatic ductal adenocarinoma, as well as to collect preliminary immune modulation and…
- Trial name
- NCT02021422
- Testing
- anakinra, Oxaliplatin, Irinotecan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor Research Institute
Fibrodysplasia Ossificans Progressiva (FOP)
IL1 Inhibition in FOP
This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP.
- Trial name
- NCT06724562
- Testing
- Anti-IL1 Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Sensorineural Hearing Loss, Autoimmune Inner Ear Disease
A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
The purpose of this study is to determine if Anakinra (an interleukin-1 receptor antagonist) can improve hearing thresholds in those patients with Autoimmune Inner Ear Disease (AIED) that did not respond to oral steroid therapy…
- Trial name
- NCT01267994
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Andrea Vambutas
Type 2 Diabetes
Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist
Aim: To investigate the therapeutic potential of IL-1Ra in type 2 diabetes. Rationale: Since the major defect leading to a decrease in b-cell mass in type 2 diabetes is increased apoptosis, therapeutic approaches designed to…
- Trial name
- NCT00303394
- Testing
- IL-1Ra
- Where
- 2 sites in Denmark, Switzerland
- Volunteers
- 72 people
- Sponsor
- University of Zurich
Prematurity; Extreme, Inflammation
Anakinra for Preterm Infants Pilot
Phase I/II study of anakinra to prevent the impact of perinatal inflammation in extremely premature infants.
- Trial name
- NCT05280340
- Testing
- Anakinra
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 25 people
- Sponsor
- Monash Medical Centre
COVID-19, Virus Diseases
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 (COVID-19) associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation.
- Conditions
- COVID-19, Virus Diseases, Macrophage Activation Syndrome, Corona Virus Infection
- Trial name
- ESCAPE (NCT04339712)
- Testing
- Anakinra, Tocilizumab
- Where
- 17 sites in Greece
- Volunteers
- 102 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Polymyositis, Dermatomyositis
Anakinra in Myositis
To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies.
- Conditions
- Polymyositis, Dermatomyositis, Inclusion Body Myositis
- Trial name
- NCT01165008
- Testing
- Anakinra
- Where
- Sweden
- Sponsor
- Karolinska Institutet